ATE145556T1 - Verwendung von interleukin-4 zur behandlung der festen tumoren - Google Patents

Verwendung von interleukin-4 zur behandlung der festen tumoren

Info

Publication number
ATE145556T1
ATE145556T1 AT91918403T AT91918403T ATE145556T1 AT E145556 T1 ATE145556 T1 AT E145556T1 AT 91918403 T AT91918403 T AT 91918403T AT 91918403 T AT91918403 T AT 91918403T AT E145556 T1 ATE145556 T1 AT E145556T1
Authority
AT
Austria
Prior art keywords
pct
solid tumors
interleukin
date mar
treat solid
Prior art date
Application number
AT91918403T
Other languages
English (en)
Inventor
Marian L Plunkett
Joseph J Catino
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE145556T1 publication Critical patent/ATE145556T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT91918403T 1990-09-06 1991-09-03 Verwendung von interleukin-4 zur behandlung der festen tumoren ATE145556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57896890A 1990-09-06 1990-09-06

Publications (1)

Publication Number Publication Date
ATE145556T1 true ATE145556T1 (de) 1996-12-15

Family

ID=24315064

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91918403T ATE145556T1 (de) 1990-09-06 1991-09-03 Verwendung von interleukin-4 zur behandlung der festen tumoren

Country Status (12)

Country Link
US (1) US5382427A (de)
EP (1) EP0552243B1 (de)
JP (1) JPH06501017A (de)
KR (1) KR100229974B1 (de)
AT (1) ATE145556T1 (de)
AU (1) AU661979B2 (de)
CA (1) CA2091170A1 (de)
DE (1) DE69123361T2 (de)
DK (1) DK0552243T3 (de)
GR (1) GR3022321T3 (de)
HU (1) HU215389B (de)
WO (1) WO1992004044A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490006B1 (de) * 1990-12-13 1994-06-22 Schering-Plough Pharmazeutische Zusammensetzungen zur Behandlung von bösartigen B-Zellenkrankheiten
US5679338A (en) * 1994-05-12 1997-10-21 Osteoarthritis Science, Inc. Use of IL-4 for inhibition of the breakdown of articular cartilage and other tissues
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
ATE338813T1 (de) * 1995-03-17 2006-09-15 Univ California Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
RU2115429C1 (ru) * 1997-07-22 1998-07-20 Закрытое акционерное общество "Фосфосорб" Рекомбинантный иммунотоксин на основе дифтерийного токсина и интерлейкина-2 (дт 482-il2) и способ его получения
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
EP1418936A2 (de) * 2001-05-09 2004-05-19 Alk-Abell A/S Pharmazeutische zusammensetzungen zur prophylaxe oder behandlung von th1- und th2-zelle verwandten erkrankungen, durch modulierung des th1/th2 verhältnisses
EP4285913A1 (de) * 2022-05-30 2023-12-06 Ecole Polytechnique Fédérale de Lausanne (EPFL) Hochwirksame adoptive t-zelltherapie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302429B1 (de) * 1987-08-03 1993-07-28 Tasuku Honjo Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria

Also Published As

Publication number Publication date
CA2091170A1 (en) 1992-03-07
HUT63769A (en) 1993-10-28
WO1992004044A1 (en) 1992-03-19
HU215389B (hu) 1998-12-28
DK0552243T3 (da) 1997-03-10
DE69123361T2 (de) 1997-04-30
EP0552243B1 (de) 1996-11-27
AU661979B2 (en) 1995-08-17
KR100229974B1 (ko) 1999-11-15
DE69123361D1 (de) 1997-01-09
AU8850591A (en) 1992-03-30
US5382427A (en) 1995-01-17
EP0552243A1 (de) 1993-07-28
HU9300624D0 (en) 1993-05-28
JPH06501017A (ja) 1994-01-27
GR3022321T3 (en) 1997-04-30

Similar Documents

Publication Publication Date Title
DE69123361D1 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
DE69120430D1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
DE69424915D1 (de) Verwendung von 1-2-4-Benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
ATE174218T1 (de) Verwendung von leflunomid zur hemmung von interleukin 1 beta
DK471386D0 (da) Farmaceutisk komposition til behandling af leukopeni
GB8805792D0 (en) Medicaments
ATE143260T1 (de) Verwendung von (s)-isofluran und (s)-desfluran zur anästhesie sowie entsprechende arzneimittelzubereitungen
ATE174219T1 (de) Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
DE69315085D1 (de) 1,4-disubstituierte piperazine zur behandlung von asthma und entzündungen der atemwege
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
ATE289823T1 (de) Erhöhung der migration oder proliferation von keratinocyten
DE69021257D1 (de) Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL.
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
ATE174220T1 (de) Verwendung von leflunomid zur hemmung von interleukin 8
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
DE69528473D1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
DE3881703D1 (de) Behandlung zur verbesserung der eigenschaften von keratintextilmaterialien.
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee